Tuberculosis Effector Functions during Human 1 / PD-Ligand 2 Pathway Inhibits T Cell Programmed Death ( PD )-1 : PD-Ligand

[1]  J. Ernst,et al.  Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs , 2008, The Journal of experimental medicine.

[2]  A. Issekutz,et al.  Cross-Talk between CD31 and the Signaling Lymphocytic Activation Molecule—Associated Protein during Interferon-γ Production against Mycobacterium tuberculosis , 2007 .

[3]  Wenda Gao,et al.  PD‐L2 expression extends beyond dendritic cells/macrophages to B1 cells enriched for VH11/VH12 and phosphatidylcholine binding , 2007, European journal of immunology.

[4]  G. Freeman,et al.  Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. , 2007, Immunity.

[5]  Lieping Chen,et al.  The new B7s: playing a pivotal role in tumor immunity. , 2007, Journal of immunotherapy.

[6]  G. Freeman,et al.  The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection , 2007, Nature Immunology.

[7]  G. Freeman,et al.  PD-1:PD-L1 Interactions Contribute to the Functional Suppression of Virus-Specific CD8+ T Lymphocytes in the Liver1 , 2007, The Journal of Immunology.

[8]  R. Koup,et al.  PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection , 2006, The Journal of experimental medicine.

[9]  B. Kwon,et al.  Functional Dichotomy between OX40 and 4-1BB in Modulating Effector CD8 T Cell Responses1 , 2006, The Journal of Immunology.

[10]  Philip J. R. Goulder,et al.  PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression , 2006, Nature.

[11]  M. Massari,et al.  PD-1 Expression in Acute Hepatitis C Virus (HCV) Infection Is Associated with HCV-Specific CD8 Exhaustion , 2006, Journal of Virology.

[12]  M. Willart,et al.  Contribution of the PD‐1 ligands/PD‐1 signaling pathway to dendritic cell‐mediated CD4+ T cell activation , 2006, European journal of immunology.

[13]  R. Balderas,et al.  Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction , 2006, Nature Medicine.

[14]  J. Becker,et al.  Tumor infiltrating lymphocytes in seminoma lesions comprise clonally expanded cytotoxic T cells , 2006, International journal of cancer.

[15]  V. García,et al.  Inducible Costimulator: A Modulator of IFN-γ Production in Human Tuberculosis1 , 2006, The Journal of Immunology.

[16]  A. Sharpe,et al.  Tissue expression of PD-L1 mediates peripheral T cell tolerance , 2006, The Journal of experimental medicine.

[17]  H. Blum,et al.  Expression of the Interleukin-7 Receptor Alpha Chain (CD127) on Virus-Specific CD8+ T Cells Identifies Functionally and Phenotypically Defined Memory T Cells during Acute Resolving Hepatitis B Virus Infection , 2006, Journal of Virology.

[18]  D. Graham,et al.  Expression of B7-H1 on Gastric Epithelial Cells: Its Potential Role in Regulating T Cells during Helicobacter pylori Infection1 , 2006, The Journal of Immunology.

[19]  M. Tsai,et al.  Mast Cells Enhance T Cell Activation: Importance of Mast Cell Costimulatory Molecules and Secreted TNF1 , 2006, The Journal of Immunology.

[20]  R. Ahmed,et al.  Restoring function in exhausted CD8 T cells during chronic viral infection , 2006, Nature.

[21]  T. Kawabe,et al.  T-helper type 1/T-helper type 2 balance in malignant pleural effusions compared to tuberculous pleural effusions. , 2005, Chest.

[22]  M. Ostrowski,et al.  Enhancement of HIV-Specific CD8 T Cell Responses by Dual Costimulation with CD80 and CD137L1 , 2005, The Journal of Immunology.

[23]  G. Zhu,et al.  B7‐H1 (CD274) inhibits the development of herpetic stromal keratitis (HSK) , 2005, FEBS letters.

[24]  E. Mittendorf,et al.  Evaluation of the CD107 cytotoxicity assay for the detection of cytolytic CD8+ cells recognizing HER2/neu vaccine peptides , 2005, Breast Cancer Research and Treatment.

[25]  J. Belisle,et al.  Peripheral Blood and Pleural Fluid Mononuclear Cell Responses to Low-Molecular-Mass Secretory Polypeptides of Mycobacterium tuberculosis in Human Models of Immunity to Tuberculosis , 2005, Infection and Immunity.

[26]  G. Zhu,et al.  Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. , 2005, Cancer research.

[27]  P. Loke,et al.  Emerging mechanisms of immune regulation: the extended B7 family and regulatory T cells , 2004, Arthritis research & therapy.

[28]  G. Freeman,et al.  PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Lieping Chen.  Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity , 2004, Nature Reviews Immunology.

[30]  D. Émilie,et al.  Induction of Tolerance by Porphyromonas gingivalis on APCs: a Mechanism Implicated in Periodontal Infection , 2004, Journal of dental research.

[31]  V. García,et al.  Expression of Signaling Lymphocytic Activation Molecule- Associated Protein Interrupts IFN-γ Production in Human Tuberculosis 1 , 2004, The Journal of Immunology.

[32]  G. Freeman,et al.  Endothelial expression of PD‐L1 and PD‐L2 down‐regulates CD8+ T cell activation and cytolysis , 2003, European journal of immunology.

[33]  G. Freeman,et al.  Regulation of PD‐1, PD‐L1, and PD‐L2 expression during normal and autoimmune responses , 2003, European journal of immunology.

[34]  R. Koup,et al.  Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. , 2003, Journal of immunological methods.

[35]  P. Loke,et al.  PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[36]  I. Wang,et al.  Program Death-1 Engagement Upon TCR Activation Has Distinct Effects on Costimulation and Cytokine-Driven Proliferation: Attenuation of ICOS, IL-4, and IL-21, But Not CD28, IL-7, and IL-15 Responses , 2003, The Journal of Immunology.

[37]  Haidong Dong,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[38]  G. Freeman,et al.  PD‐1:PD‐L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL‐2 , 2002, European journal of immunology.

[39]  G. Aversa,et al.  Signaling Lymphocytic Activation Molecule Expression and Regulation in Human Intracellular Infection Correlate with Th1 Cytokine Patterns1 , 2001, The Journal of Immunology.

[40]  E. Chan,et al.  What is the role of nitric oxide in murine and human host defense against tuberculosis?Current knowledge. , 2001, American journal of respiratory cell and molecular biology.

[41]  S. Kaufmann,et al.  How can immunology contribute to the control of tuberculosis? , 2001, Nature Reviews Immunology.

[42]  P. Newman,et al.  Inhibition of antigen-receptor signaling by Platelet Endothelial Cell Adhesion Molecule-1 (CD31) requires functional ITIMs, SHP-2, and p56(lck). , 2001, Blood.

[43]  D. Pardoll,et al.  B7-Dc, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells , 2001, The Journal of experimental medicine.

[44]  G. Freeman,et al.  PD-L2 is a second ligand for PD-1 and inhibits T cell activation , 2001, Nature Immunology.

[45]  S. Dorman,et al.  Interferon-γ and interleukin-12 pathway defects and human disease , 2000 .

[46]  G. Freeman,et al.  Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.

[47]  S. Dzik.  B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin 10 secretion , 2000 .

[48]  T. Honjo,et al.  Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. , 1999, Immunity.

[49]  A. Sharpe,et al.  CTLA-4 and T cell activation. , 1999, Current opinion in immunology.

[50]  K. Lukacs,et al.  Protection against Mycobacterium tuberculosisInfection by CD8+ T Cells Requires the Production of Gamma Interferon , 1998, Infection and Immunity.

[51]  J. Allison,et al.  The emerging role of CTLA-4 as an immune attenuator. , 1997, Immunity.

[52]  Y. Tanaka,et al.  Single-cell cytokine analysis of gamma delta T cell responses to nonpeptide mycobacterial antigens. , 1997, Journal of immunology.

[53]  T. Honjo,et al.  Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. , 1996, International immunology.

[54]  J. Abrams,et al.  T-cell cytokine responses in human infection with Mycobacterium tuberculosis , 1995, Infection and immunity.

[55]  Dinakar,et al.  T cell cytokine responses in persons with tuberculosis and human immunodeficiency virus infection. , 1994, The Journal of clinical investigation.

[56]  T. Honjo,et al.  Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. , 1992, The EMBO journal.

[57]  J. Ellner,et al.  The immunology of tuberculous pleurisy. , 1988, Seminars in respiratory infections.

[58]  G. Freeman,et al.  PD-1:PD-L1 Interactions Contribute to the Functional Suppression of Virus-Specific CD8 T Lymphocytes in the Liver , 2007 .

[59]  J. Prieto,et al.  [The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases]. , 2006, Anales del sistema sanitario de Navarra.

[60]  Moses Rodriguez,et al.  Induction of a gene expression program in dendritic cells with a cross-linking IgM antibody to the co-stimulatory molecule B7-DC. , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[61]  A. Sharpe,et al.  This information is current as Responses Facilitate Robust CD 8 and CD 4 Recall 4-1 BB and OX 40 Act Independently to and , 2004 .

[62]  G. Zhu,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[63]  B. Spellberg,et al.  Type 1/Type 2 immunity in infectious diseases. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.